Annemans et al. [65]
|
50+
|
37.6-63.9 %, age-dependent
|
No waningb
|
20 %
|
EUR 141.39c
|
Bilcke et al. [38]
|
60-85
|
Age-dependent (values are reported graphically only)
|
Consideration of waning depends on the choice of scenario
|
30 %
|
EUR 106.95d
|
Bilcke et al. [30]
|
50 or 60
|
77 %e
|
Duration of protection of 7.5 years or lifelong protection
|
30 % or 70 %
|
EUR 103.38d
|
Bresse et al. [66]
|
65+
|
18-64 %, age-dependent
|
4.15 % per year and vaccine efficacy was set to zero after 10 years
|
20 %
|
EUR 117f
|
Brisson et al. [67]
|
50-80
|
26-75 %, age-dependent
|
No waningb
|
Not specified
|
EUR 108.60
|
de Boer et al. [40]
|
60-75
|
41.2-69.4 %, age-dependent
|
8.3 % per year (= duration of protection of 12 years)
|
Not specified
|
EUR 89.10d
|
Edmunds et al. [68]
|
65
|
30-70 %
|
Duration of protection of 2.5 years to life long
|
60 %
|
EUR 122.13d,g
|
Hornberger et al. [28]
|
69
|
Modelled by applying age-specific incidence of HZ in vaccine and placebo-treated arm of the clinical study, age-dependent
|
Duration of protection of 30 years
|
Not specified
|
EUR 43.85-438.46d,h
|
Moore et al. [69]
|
50+
|
37.6-63.9 %, age-dependent
|
No waningb
|
40 %
|
EUR 143.28d
|
Najafzadeh et al. [26]
|
60+
|
Modelled by applying age-specific incidence of HZ in vaccine and placebo-treated arm of the clinical study, age-dependent
|
4.5 % per year
|
Not specified
|
EUR 101.83
|
Pellissier et al. [70]
|
60+
|
27.1-69.8 %, age-dependent
|
No waningb
|
Not specified
|
EUR 147.32d
|
Rothberg et al. [42]
|
60-80
|
Age-dependent
|
Waning considered but not quantified
|
Not specified
|
EUR 134.74d
|
Szucs et al. [71]
|
70-79
|
37.60-63.9 %, age-dependent
|
No waningb
|
20 %
|
EUR 143.09d
|
Ultsch et al. [39]
|
50-80
|
13.22-69.8 %, age-dependent
|
8.3 % per year following 10 years of stable vaccine efficacy
|
20 %
|
EUR 147.48d
|
van Hoek et al. [72]
|
60-75
|
31-95 % (based on 15 different take and waning scenarios), age-dependent
|
Duration of protection of 3.6-100 years (based on 15 different take and waning scenarios)
|
73.5 %
|
EUR 88.36d
|
van Hoek et al. [33]
|
75
|
Data from van Hoek et al. [72]
|
Data from van Hoek et al. [72]
|
70 %
|
EUR 86.37d
|
van Lier et al. [41]
|
60-80
|
Data from van Hoek et al. [72]
|
Duration of protection of 7.5 years
|
75 %
|
EUR 81.54d
|